Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2010

01.12.2010 | Epidemiology

BRCA1/2 test results impact risk management attitudes, intentions, and uptake

verfasst von: Suzanne C. O’Neill, Heiddis B. Valdimarsdottir, Tiffani A. DeMarco, Beth N. Peshkin, Kristi D. Graves, Karen Brown, Karen E. Hurley, Claudine Isaacs, Sharon Hecker, Marc D. Schwartz

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Women who receive positive or uninformative BRCA1/2 test results face a number of decisions about how to manage their cancer risk. The purpose of this study was to prospectively examine the effect of receiving a positive versus uninformative BRCA1/2 genetic test result on the perceived pros and cons of risk-reducing mastectomy (RRM) and risk-reducing oophorectomy (RRO) and breast cancer screening. We further examined how perceived pros and cons of surgery predict intention for and uptake of surgery. 308 women (146 positive, 162 uninformative) were included in RRM and breast cancer screening analyses. 276 women were included in RRO analyses. Participants completed questionnaires at pre-disclosure baseline and 1-, 6-, and 12-months post-disclosure. We used linear multiple regression to assess whether test result contributed to change in pros and cons and logistic regression to predict intentions and surgery uptake. Receipt of a positive BRCA1/2 test result predicted stronger pros for RRM and RRO (P < 0.001), but not perceived cons of RRM and RRO. Pros of surgery predicted RRM and RRO intentions in carriers and RRO intentions in uninformatives. Cons predicted RRM intentions in carriers. Pros and cons predicted carriers’ RRO uptake in the year after testing (P < 0.001). Receipt of BRCA1/2 mutation test results impacts how carriers see the positive aspects of RRO and RRM and their surgical intentions. Both the positive and negative aspects predict uptake of surgery.
Literatur
1.
Zurück zum Zitat Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333CrossRefPubMed Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25:1329–1333CrossRefPubMed
2.
Zurück zum Zitat Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:136–1310 Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:136–1310
3.
Zurück zum Zitat Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328–2335CrossRefPubMed Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328–2335CrossRefPubMed
5.
6.
Zurück zum Zitat Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615CrossRefPubMed Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615CrossRefPubMed
7.
Zurück zum Zitat Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622CrossRefPubMed Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622CrossRefPubMed
8.
Zurück zum Zitat Vink GR, van Asperen CJ, Devilee P et al (2005) Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines. Eur J Hum Genet 13:525–527CrossRefPubMed Vink GR, van Asperen CJ, Devilee P et al (2005) Unclassified variants in disease-causing genes: nonuniformity of genetic testing and counselling, a proposal for guidelines. Eur J Hum Genet 13:525–527CrossRefPubMed
10.
Zurück zum Zitat Domchek SM, Gaudet MM, Stopfer JE et al (2009) Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat 119:409–414CrossRef Domchek SM, Gaudet MM, Stopfer JE et al (2009) Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Res Treat 119:409–414CrossRef
11.
Zurück zum Zitat Herrinton LJ, Barlow WE, Yu O et al (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23:4275–4286CrossRefPubMed Herrinton LJ, Barlow WE, Yu O et al (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23:4275–4286CrossRefPubMed
12.
Zurück zum Zitat McDonnell SK, Schaid DJ, Myers JL et al (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938–3943PubMed McDonnell SK, Schaid DJ, Myers JL et al (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 19:3938–3943PubMed
13.
Zurück zum Zitat Peralta EA, Ellenhorn JD, Wagman LD et al (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180:439–445CrossRefPubMed Peralta EA, Ellenhorn JD, Wagman LD et al (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180:439–445CrossRefPubMed
14.
Zurück zum Zitat Tilanus-Linthorst M, Verhoog L, Obdeijn IM et al (2002) A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102:91–95CrossRefPubMed Tilanus-Linthorst M, Verhoog L, Obdeijn IM et al (2002) A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer 102:91–95CrossRefPubMed
15.
Zurück zum Zitat Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–97CrossRefPubMed Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80–97CrossRefPubMed
16.
Zurück zum Zitat Madalinska JB, Hollenstein J, Bleiker E et al (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890–6898CrossRefPubMed Madalinska JB, Hollenstein J, Bleiker E et al (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23:6890–6898CrossRefPubMed
17.
Zurück zum Zitat Parker WH, Jacoby V, Shoupe D et al (2009) Effect of bilateral oophorectomy on women’s long-term health. Womens Health (Lond Engl) 5:565–576 Parker WH, Jacoby V, Shoupe D et al (2009) Effect of bilateral oophorectomy on women’s long-term health. Womens Health (Lond Engl) 5:565–576
18.
Zurück zum Zitat Verhoeven MO, van der Mooren MJ, Teerlink T et al (2009) The influence of physiological and surgical menopause on coronary heart disease risk markers. Menopause 16:37–49CrossRefPubMed Verhoeven MO, van der Mooren MJ, Teerlink T et al (2009) The influence of physiological and surgical menopause on coronary heart disease risk markers. Menopause 16:37–49CrossRefPubMed
19.
Zurück zum Zitat Rini C, O’Neill SC, Valdimarsdottir H et al (2009) Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results. Health Psychol 28:569–578CrossRefPubMed Rini C, O’Neill SC, Valdimarsdottir H et al (2009) Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results. Health Psychol 28:569–578CrossRefPubMed
20.
Zurück zum Zitat Fang CY, Miller SM, Malick J et al (2003) Psychosocial correlates of intention to undergo prophylactic oophorectomy among women with a family history of ovarian cancer. Prev Med 37:424–431CrossRefPubMed Fang CY, Miller SM, Malick J et al (2003) Psychosocial correlates of intention to undergo prophylactic oophorectomy among women with a family history of ovarian cancer. Prev Med 37:424–431CrossRefPubMed
21.
Zurück zum Zitat Litton JK, Westin SN, Ready K et al (2009) Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115:1598–1604CrossRefPubMed Litton JK, Westin SN, Ready K et al (2009) Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer 115:1598–1604CrossRefPubMed
22.
Zurück zum Zitat Warner E, Messersmith H, Causer P et al (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148:671–679PubMed Warner E, Messersmith H, Causer P et al (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148:671–679PubMed
23.
Zurück zum Zitat Schwartz MD, Valdimarsdottir HB, DeMarco TA et al (2009) Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol 28:11–19CrossRefPubMed Schwartz MD, Valdimarsdottir HB, DeMarco TA et al (2009) Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol 28:11–19CrossRefPubMed
24.
Zurück zum Zitat Schwartz MD, Peshkin BN, Hughes C et al (2002) Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 20:514–520CrossRefPubMed Schwartz MD, Peshkin BN, Hughes C et al (2002) Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 20:514–520CrossRefPubMed
25.
Zurück zum Zitat Schwartz MD, Peshkin BN, Tercyak KP et al (2005) Decision making and decision support for hereditary breast-ovarian cancer susceptibility. Health Psychol 24:S78–S84CrossRefPubMed Schwartz MD, Peshkin BN, Tercyak KP et al (2005) Decision making and decision support for hereditary breast-ovarian cancer susceptibility. Health Psychol 24:S78–S84CrossRefPubMed
26.
Zurück zum Zitat Meiser B, Butow P, Barratt A et al (1999) Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 75:122–129CrossRefPubMed Meiser B, Butow P, Barratt A et al (1999) Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer. Gynecol Oncol 75:122–129CrossRefPubMed
27.
Zurück zum Zitat Meiser B, Butow P, Friedlander M et al (2000) Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol 18:2250–2257PubMed Meiser B, Butow P, Friedlander M et al (2000) Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol 18:2250–2257PubMed
28.
Zurück zum Zitat van Dijk S, Otten W, Zoeteweij MW et al (2003) Genetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessment. Br J Cancer 88:1675–1681CrossRefPubMed van Dijk S, Otten W, Zoeteweij MW et al (2003) Genetic counselling and the intention to undergo prophylactic mastectomy: effects of a breast cancer risk assessment. Br J Cancer 88:1675–1681CrossRefPubMed
29.
Zurück zum Zitat Botkin JR, Smith KR, Croyle RT et al (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118A:201–209CrossRefPubMed Botkin JR, Smith KR, Croyle RT et al (2003) Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118A:201–209CrossRefPubMed
30.
Zurück zum Zitat Peshkin BN, Schwartz MD, Isaacs C et al (2002) Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 11:1115–1118PubMed Peshkin BN, Schwartz MD, Isaacs C et al (2002) Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 11:1115–1118PubMed
31.
Zurück zum Zitat Arrington AK, Jarosek SL, Virnig BA et al (2009) Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol 16:2697–2704CrossRefPubMed Arrington AK, Jarosek SL, Virnig BA et al (2009) Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol 16:2697–2704CrossRefPubMed
32.
Zurück zum Zitat Jones NB, Wilson J, Kotur L et al (2009) Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol 16:2691–2696CrossRefPubMed Jones NB, Wilson J, Kotur L et al (2009) Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol 16:2691–2696CrossRefPubMed
33.
Zurück zum Zitat McGuire KP, Santillan AA, Kaur P et al (2009) Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 16:2682–2690CrossRefPubMed McGuire KP, Santillan AA, Kaur P et al (2009) Are mastectomies on the rise? A 13-year trend analysis of the selection of mastectomy versus breast conservation therapy in 5865 patients. Ann Surg Oncol 16:2682–2690CrossRefPubMed
34.
Zurück zum Zitat Sheeran P (2002) Intention-behavior relations: a conceptual and empirical review. Eur Rev Soc Psychol 12:1–36CrossRef Sheeran P (2002) Intention-behavior relations: a conceptual and empirical review. Eur Rev Soc Psychol 12:1–36CrossRef
35.
Zurück zum Zitat Fishbein M, Hennessy M, Kamb M et al (2001) Using intervention theory to model factors influencing behavior change. Project RESPECT. Eval Health Prof 24:363–384CrossRefPubMed Fishbein M, Hennessy M, Kamb M et al (2001) Using intervention theory to model factors influencing behavior change. Project RESPECT. Eval Health Prof 24:363–384CrossRefPubMed
36.
Zurück zum Zitat Morgan D, Sylvester H, Lucas FL et al (2009) Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer 8:277–287CrossRefPubMed Morgan D, Sylvester H, Lucas FL et al (2009) Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting. Fam Cancer 8:277–287CrossRefPubMed
Metadaten
Titel
BRCA1/2 test results impact risk management attitudes, intentions, and uptake
verfasst von
Suzanne C. O’Neill
Heiddis B. Valdimarsdottir
Tiffani A. DeMarco
Beth N. Peshkin
Kristi D. Graves
Karen Brown
Karen E. Hurley
Claudine Isaacs
Sharon Hecker
Marc D. Schwartz
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2010
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-0881-4

Weitere Artikel der Ausgabe 3/2010

Breast Cancer Research and Treatment 3/2010 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.